The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Michele Cavo

Istituto di Ematologia ed Oncologia Medica [Seràgnoli]

Università di Bologna

Bologn

Italy

[email]@med.unibo.it

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Istituto di Ematologia ed Oncologia Medica [Seràgnoli], Università di Bologna, Bologn, Italy. 2000 - 2007

References

  1. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., Narni, F., Carubelli, A., Masini, L., Catalano, L., Fiacchini, M., de Vivo, A., Gozzetti, A., Lazzaro, A., Tura, S., Baccarani, M. J. Clin. Oncol. (2007) [Pubmed]
  2. Current status of bortezomib in the treatment of multiple myeloma. Cavo, M. Curr. Hematol. Malig. Rep (2007) [Pubmed]
  3. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Cavo, M. Leukemia (2006) [Pubmed]
  4. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Cavo, M., Zamagni, E., Tosi, P., Tacchetti, P., Cellini, C., Cangini, D., de Vivo, A., Testoni, N., Nicci, C., Terragna, C., Grafone, T., Perrone, G., Ceccolini, M., Tura, S., Baccarani, M. Blood (2005) [Pubmed]
  5. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Cavo, M., Zamagni, E., Tosi, P., Cellini, C., Cangini, D., Tacchetti, P., Testoni, N., Tonelli, M., de Vivo, A., Palareti, G., Tura, S., Baccarani, M. Haematologica (2004) [Pubmed]
  6. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Cavo, M., Benni, M., Ronconi, S., Fiacchini, M., Gozzetti, A., Zamagni, E., Cellini, C., Tosi, P., Baccarani, M., Tura, S. Haematologica (2002) [Pubmed]
  7. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Cavo, M., Terragna, C., Martinelli, G., Ronconi, S., Zamagni, E., Tosi, P., Lemoli, R.M., Benni, M., Pagliani, G., Bandini, G., Tura, S. Blood (2000) [Pubmed]
 
WikiGenes - Universities